Humacyte, Inc. (HUMA) Financial Analysis & Valuation | Quarter Chart

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platfo... more
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengi... more

Company facts

Reported company information and share structure.

Company Share structure
Market Cap$98.38MExchangeNASDAQ
SectorHealthcareIndustryBiotechnology
CountryUSCEOLaura E. Niklason
IPO Date2020-12-01CAGR-16.9%
Employees184Websitewww.humacyte.com
Div. YieldPayout Ratio
Buy Back YieldTotal Yield
HUMA chart loading...

Key metrics

Reported fundamentals and market-derived technical indicators.

Fundamentals Technicals
EV$175.01MP/E-0.98Forward P/E-2.37PEG
P/S631.98P/B59.84P/CF-19.31P/FCF-13.73
Sales$2.12MSales 1Y-73.64%Sales 3Y6741.94%Sales 5Y12.64%
EPS$-0.6EPS 1Y13.11%EPS 3Y-54.14%EPS 5Y-93.13%
Sales QoQ-17.98%EPS QoQ79.78%Sales QoQ Avg25.05%EPS QoQ Avg5.33%
Gross Margin-666.81%Operating Margin-5240.78%Profit Margin-4560.82%ROCE-90.27%
ROA-70%ROE-938%Altman Z Score-8.64Piotroski Score3
Current Ratio6.21Quick Ratio5.74Cash Ratio5.35Op. CF Ratio-1.48
Debt/Equity2.12Debt/Assets0.48Lt Debt/Equity2.07Lt Debt/Cap.0.67
Intrst Cov.-10.8Inventory Turnover2.33Asset Turnover0.02Receivables Turnover6.43
Enterprise Value$175.01MP/E Ratio-0.98
Forward P/E-2.37PEG Ratio
P/S Ratio631.98P/B Ratio59.84
P/CF Ratio-19.31P/FCF Ratio-13.73
EPS$-0.6EPS Growth 1Y13.11%
EPS Growth 3Y-54.14%EPS Growth 5Y-93.13%
Revenue Growth 1Y-73.64%Gross Margin-666.81%
Operating Margin-5240.78%Profit Margin-4560.82%
ROE-938%ROA-70%
ROCE-90.27%Current Ratio6.21
Quick Ratio5.74Cash Ratio5.35
Debt/Equity2.12Interest Coverage-10.8
Altman Z Score-8.64Piotroski Score3